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Abstract
To develop a long-circulating theragnostics, meaning therapeutics and diagnostics for MR-guided HIFU ablation, we
designed and prepared Gd-C5F12-phospholipid nanobubbles (PLNs) 30–100 nm in diameter. The biochemical and physical
characterization of Gd-C5F12-PLNs were performed. Since Gd-C5F12-PLN-50 (W=50 nm) and Gd-C5F12-PLN-100 (W=100 nm)
enhanced the hyperthermal effect of HIFU size- and concentration-dependently in a tissue-mimicking phantom, its
circulation, distribution, tumor accumulation and tumor ablation were examined in tumor-bearing mice. The plasma-half life
of Gd-C5F12-PLNs was longer than 1.5 hrs. Gd-C5F12-PLNs mainly accumulated in the liver and the spleen, suggesting that
they are slowly secreted through the hepatobiliary pathway. Monitored by the T1 signal intensity of MR, Gd-C5F12-PLNs
accumulated in tumor tissues for 8 hours in mice. HIFU with Gd-C5F12-PLN-100 showed the increased tumor ablation area as
compared with HIFU alone. The results suggest that Gd-C5F12-PLNs exhibit a potential theragnostics for MR-guided HIFU
ablation.
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Introduction
Minimally or non-invasive hyperthermal ablation of tumor
tissues has been used for palliative and curative purposes [1–4].
High-intensity focused ultrasound (HIFU) ablation is even less
invasive than other minimally-invasive thermal ablation tech-
niques, such as radiofrequency, laser, and microwave ablation.
Image guidance, such as ultrasound and MRI, allows HIFU
ablation to deliver high intensity ultrasound (500–10,000 W/cm
2)
precisely focused on the tumor, preventing surrounding tissues
from injury and complications.
Although the concept of HIFU makes it ideal for tumor
ablation, it does have some shortcomings. Because the ablation
zone for a single HIFU sonication is small, HIFU can require
relatively long procedures, especially for large tumors [4]. In
addition, hypervascular tumors require relatively high-energy
HIFU sonication, which can have adverse effects such as heating
intervening normal tissues including the skin [3,5].
Microbubbles increase heat generation under HIFU mainly by
increasing inertial cavitation [6]. For example, DefinityH increased
the ultrasound thermal effect in tissue mimicking phantoms [7],
SonoVueH enhanced HIFU ablation of rabbit hepatic VX2
tumors [8], and LevovistH enhanced HIFU ablation in rat liver
tumors [9]. Microbubble agents also improved the low therapeutic
efficiency of kidney HIFU in rabbit [10] and goat [11] studies, and
cavitation from vaporized albumin-based nanoemulsion acceler-
ated HIFU-mediated heating [12]. It suggests that gas-filled
microbubbles (W=1–5 micron) have remarkable effects on HIFU-
assisted tumor ablation. However, the plasma half-life of clinical
microbubble contrast agents which is 10–12 min according to
manufacturer’s information is too short to be used as therapeutic
enhancers for HIFU treatment in patients.
Thus, we designed phospholipid nanobubbles (PLNs) 30–
100 nm in diameter that circulate longer than microbubbles.
The PLNs also contain perfluoropentane (C5F12) gas to enhance
the thermal efficacy of HIFU therapy. The C5F12-PLNs were then
conjugated to gadolinium (Gd) to be detectable by MR.
The aim of this study was to determine if Gd-C5F12-PLN could
be a theragnostics for hyperthermal tumor ablation by MR-guided
HIFU. Various sizes (W=30, 50, 100 nm) of Gd-C5F12-PLNs were
prepared and their chemical characterizations were performed.
The potential efficacy of Gd-C5F12-PLNs in hyperthermal therapy
with HIFU was investigated in vitro and in vivo.
Materials and Methods
Preparation of Gd-C5F12-PLNs
Phospholipid nanobubbles were prepared according to the
manufacturer’s instructions with modifications,http://www.
avantilipids.com.. Briefly, 25.3 mM of 1,2-dioctadecanoyl-sn-
glycero-3-phosphocholine (DSPC), 22.2 mM of 1,2-dioleoyl-sn-
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350] (ammonium salt) (DOPE-PEG350), 22.8 mM of 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetria-
minepentaacetic acid (ammonium salt) (DMPE-DTPA) and
17.7 mM of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-350] (ammonium salt) (DSPE-
PEG350) (AvantiH POLAR LIPID, Inc., Alabaster, AL) were
mixed in chloroform (Sigma-Aldrich). To make the gas-filled
nanobubble, 50 ml/ml of decafluoropentane (Sigma-Aldrich, St.
Louis, MO) were added to these preparations. An equal volume of
methanol (MERCK, Darmstadt, Germany) was added to lipid
mixture. The mixed lipid was removed under evaporation. The
lipid film was then dissolved in 1 ml of PBS. The mixture was
sonicated for 15 minutes at 55uC in water-bath. Tween 80 (Sigma-
Aldrich) was added in 75 mg/ml and sonicated again for
15 minutes at 55uC in water bath. The mixture was then loaded
into one of two pre-warmed gas-tight syringes of an Extruder
(AvantiH POLAR LIPID) with 30, 50, or 100 nm (cut-off)
polycarbonate membranes. The entire contents of the syringe
were passed through the filter and into an opposing syringe. This
process was repeated for a total of more than 11 passes. The
C5F12-PLN preparation was then chelated with Gd. Free Gd was
removed by filtering the reaction mixture through a centrifugal
filter (10,000 Da cut-off) after adding 10 ml of PBS three times.
The Gd concentration in the Gd-C5F12-PLN preparation was
determined by ICP-AES (Agilent 7500A, Palo Alto, CA). The
magnetic susceptometry was analyzed with a superconductive
quantum interference device (SQUID). The size was also
determined with DLS (Dynamic light scattering). To compare
stability of Gd-C5F12-PLNs with SonoVueH (Bracco, Milan, Italy)
which is mainly composed of phospholipids, 40 mM [P] of Gd-
C5F12-PLN-50, Gd-C5F12-PLN-100 and 5 mg/ml of SonoVueH in
prewarmed saline at 37uC were sonographed in a contrast mode
with high-frequency(40 MHz) ultrasound system(Vevo2100H,
VisualSonics, Tronto, Canada) for 1.5 hours. The bubble solution
was placed on a temperature-controlled aluminum block at 37uC
during the whole experiment. Echogenic bubbles were counted
from the real-time images and its % echogenesity was calculated.
Cytotoxicity of Gd-C5F12-PLN
The cytotoxicity of Gd-C5F12-PLN was investigated with an
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay in the mouse endothelial cell line, MS-1 (CRL-2279,
ATCC, Manassas, VA) which is a primary contacting cell for
injected PLNs in circulation. The cell lysis RIPA (radioimmuno-
precipitation assay) buffer was used as a control.
Phosphorus assay
To determine the phosphorus concentration which is the major
component of Gd-C5F12-PLN, a phosphorus assay was performed.
Up to 50 ml of the sample to be analyzed and 0.45 ml of 8.9 N
H2S04 (Sigma-Aldrich) were placed in a 15 mL conical centrifuge
tube and heated in a 150uC oven for at least 1 hour. Then, 150 ml
H2O2 was added and the solution was returned to the oven for at
least 30 min more to complete the combustion and decompose all
the peroxide. To the reaction tubes, 0.5 ml ammonium molybdate
tetra hydrate (Sigma-Aldrich) and 0.5 ml ascorbic-acid solution
(Sigma-Aldrich) in 3.9 ml deionized water were added, mixed
thoroughly, and heated for 7 minutes in a boiling water bath. The
optical density at 820 nm was recorded with a spectrophotometer
(Ultraspec 2000, Pharmacia Biotec, Cambridge, UK).
Tissue-mimicking phantom
The tissue-mimicking phantoms used in this study were
constructed from an acrylamide/bis gel according to a previous
report [13]. Briefly, the phantom was prepared from a
polyacrylamide gel mixed with egg white (Sigma-Aldrich) as a
hyperthermia indicator. The tissue-mimicking phantom consists of
10% acrylamide (Biosesang, Seomgnam, Korea), 30% egg white,
0.05% ammonium peroxodisulfate (Sigma-Aldrich), 4.5% glycer-
ol, and 0.2% TEMED (Biosesang) in degassed water with or
without Gd-C5F12-PLNs ([P]=1 mM). The solution was then
polymerized in an acrylic mold (W=36 mm, height=17 mm) to
produce a cake of tissue-mimicking phantom.
High-intensity focused ultrasound system and in vitro
HIFU ablation
The equipment used to generate high intensity focused
ultrasound is a commercially available device (TIPS, Therapy
Imaging Probe System, Philips Research, Briarcliff Manor, NY)
designed for preclinical research. , HIFU was applied to the tissue-
mimicking phantom including Gd-C5F12-PLNs with an acoustic
intensity of 5000 W/cm
2 at the focal zone (6 dB) which is
16166m m
3 and a sonication frequency of 1.0 MHz for 30 sec
(duty cycle 100%). The effects of HIFU on the phantom were
recorded with a CCD-camera and quantified by the brightness of
the white opaque lesion using public domain software (Image J
program, developed at the National Institutes of Health and
available at http://rsb.info.nih.gov/nih-image/).
Circulation time and distribution analysis of the Gd-
C5F12-PLNs in mice
To determine circulation time, Gd-C5F12-PLNs (10 mmoles of P
in 0.25 ml) were injected into BABL/c mice (Orient, Seongnam,
Korea) via the tail vein. Blood was collected from the tail vein at
various time points (30 min to 24 h) after injection. The
distribution of Gd-C5F12-PLN in various organs was measured
24 hours after injection. Animals were sacrificed, and the muscle,
kidney, liver, and spleen were harvested. The organs were then
dried at 37uC for 48 hours. Gd quantities in the blood and organs
were analyzed by Inductively Coupled Plasma-Atomic Emission
Spectrometer (ICP-AES, Agilent 7500A, Palo Alto, CA).
To examine accumulation of the Gd-C5F12-PLN in the tumor
tissue, the mouse colon cancer cell line CT-26 (5610
6 in 0.3 ml
PBS) acquired from KCLB (Seoul, Korea) was subcutaneously
injected into the left hind limbs of BABL/c nude mice. The tumor
was allowed to grow for 10 days, reaching ,10 mm in diameter.
Mice were injected with Gd-C5F12-PLN-50 or Gd-C5F12-PLN-
100 (10 mmoles of P in 0.25 ml) through the tail vein. Gd-C5F12-
PLN accumulation in the tumor tissue was monitored with T1-
weighted imaging (fast spin echo, TR/TE=350/8.5 ms, slice
thickness 1.0 mm) for 8 hours using a 7-Tesla small animal MR
scanner (BioSpin70/20USR, Bruker-Biospin, Fallanden, Switzer-
land).
In vivo HIFU ablation and MR assessment
The CT-26 tumor-bearing mice were injected with saline or
Gd-C5F12-PLN-100 (0.4 mmoles of P/kg or 0.04 mmoles Gd/kg
in 0.25 ml) through the tail vein. The tumor was treated by HIFU
using TIPS. Each animal was anesthetized with isoflurane and
placed in a custom-designed holder. The HIFU transducer was
focused on the medial plane of the tumor and coupled onto the
tumor with ultrasonic gel. HIFU was performed with ultrasound
output power adjusted in the range of 3000 W/cm
2, a frequency
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2-
area of tumor tissues. Tumor ablation was monitored by T1-
weighted MR imaging (T1WI), before and 24 hours after HIFU
treatment, performed in TR/TE=8.5/350 ms with 1.0 mm slice
thickness before and after injection of Dotarem (Guebet, Roissy,
France) with 0.1 mmoles Gd/kg through the tail vein. To measure
the area of ablated tumor tissue, each T1W image before Dotarem
injection was subtracted from the corresponding image after
injection. Animals were euthanized by carbon dioxide asphyxia-
tion after imaging and the tumor tissue was collected for
histological analysis. This study was reviewed and approved by
the Institutional Animal Care and Use Committee (Approval ID:
P-A9-502-2) of Samsung Biomedical Research Institute (SBRI)
which is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC
International) and abides by the Institute of Laboratory Animal
Resources (ILAR) guide.
Histopathological analysis
All frozen specimens were processed by both H&E and
nicotinamide adenine dinucleotide reduced (NADH) diaphorase
staining [14]. The specimens were cut to 4 mm thick and air-dried
briefly at room temperature. The tissue sections were incubated at
37uC for 1 hour in 10 ml of Tris-HCl buffer (pH 7.4) containing
10 mg of nitro blue tetrazolium (Sigma-Aldrich) and 10 mg of
NADH (Sigma-Aldrich). Specimens were washed with distilled
water, various concentrations of acetone (30%, 60%, 90%, 60%,
and 30%), and finally with distilled water. The specimens were
mounted for later review by a pathologist. H&E staining was also
performed on both frozen and paraffin-imbedded specimens using
the standard technique. The ablated area seen by H&E staining
was measured [length6width (mm
2)] from tissue sections exposed
perpendicular to the direction of HIFU propagation. The effect of
Gd-C5F12-PLN-100 on the ablation area by HIFU (n=6) was
compared with Student’s t-tests.
Results
Characterization of Gd-C5F12-PLN
The Gd-C5F12-PLN consists of a biocompatible phospholipid
backbone, perfluoropentane gas, and Gd-DTPA (Fig. 1A). Various
sizes of Gd-C5F12-PLN (W=30, 50, 100 nm) were synthesized and
its size distribution was confirmed by DLS (Fig. 1D). Gd and P
contents in the Gd-C5F12-PLNs determined by ICP-AES and
phosphorus assay, respectively were listed in Table 1. The Gd-
C5F12-PLNs contained ,0.1 mole Gd/mole P, meaning ,20% of
the DMPE-DTPA chelated Gd. The paramagnetic property of the
Gd-C5F12-PLN confirmed with a SQUID test showed that the
Gd-C5F12-PLN exhibits typical paramagnetism (Fig. 1B). The
Figure 1. Chemical characterization of Gd-C5F12-PLNs. (A) Design of Gd-C5F12-PLN. Gd-C5F12-PLN was W=30, 50, and 100nm.
(B) Paramagnetism of the Gd-C5F12-PLN from SQUID test. (C) Cytotoxicity of Gd-C5F12-PLNs in MS-1 cells. The cytotoxicity of Gd-C5F12-PLN was
investigated by MTT assay. Serially diluted cell lysis buffer (RIPA) was used as a positive control. (D) Size-distribution of Gd-C5F12-PLNs from DLS
analysis. (E) In vitro stability of Gd-C5F12-PLN-50, Gd-C5F12-PLN 2100 and SonoVue was calculated from its echogenesity using high-frequency
ultrasound.
doi:10.1371/journal.pone.0034333.g001
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in the tested concentration range (Fig. 1C). In vitro bubble stability
of Gd-C5F12-PLN-500, Gd-C5F12-PLN-100 at 37uC was signifi-
cantly higher than that of SonoVue (Fig. 1E). IC50 of Gd-C5F12-
PLN-50, Gd-C5F12-PLN-100 and SonoVue was 279.2619.53,
310.2620.53 and 90612.24 sec, respectively.
Enhanced hyperthermal effect of HIFU by Gd-C5F12-PLN
in vitro
To examine the effect of Gd-C5F12-PLN size on the
hyperthermal property of HIFU, the polyacrylamide phantom
was polymerized in the presence of three different Gd-C5F12-PLNs
in diameter (30, 50, and 100 nm). HIFU without Gd-C5F12-PLNs
did not show a significant turbidity change in the egg white of the
transparent gel phantom (Fig. 2). Gd-C5F12-PLN enhanced the
hyperthermal effect of HIFU in a size-dependent manner
(W=30,50,100 nm) (Fig. 2A), as determined by the turbidity
of the white opaque lesion induced by HIFU (Fig. 2B). Both Gd-
C5F12-PLN-50 and Gd-C5F12-PLN-100 significantly increased the
hyperthermal effect of HIFU ablation, while Gd-C5F12-PLN-30
had only a slight effect. The video files recorded during HIFU
exposure on the phantoms in the absence or presence of Gd-
C5F12-PLN-30, Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 were
shown in Supporting Information (Video S1, S2, S3, and S4,
respectively).
The concentration-dependent effect of both Gd-C5F12-PLN-50
and Gd-C5F12-PLN-100 on the hyperthermal property of HIFU
was also observed (Fig. 3A). The intensity of HIFU lesions show
Table 1. Chemical analysis of the synthesized phospholipid
nanoparticles.
[Gd] (mM) [P] (mM) [Gd]/[P]
Gd–PLN-30 2.43 28.34 0.09
Gd–PLN-50 4.39 36.57 0.12
Gd–PLN-100 4.24 39.70 0.11
Gd-C5F12–PLN-30 3.97 37.13 0.11
Gd-C5F12–PLN-50 4.14 38.34 0.11
Gd-C5F12–PLN-100 3.80 43.88 0.09
doi:10.1371/journal.pone.0034333.t001
Figure 2. Effect of Gd-C5F12-PLN on the hyperthermal property of HIFU in the tissue-mimicking gel phantom. The phantom was
monitored with a video camera while it was sonified for 1 min. The phantom was photographed after HIFU (A). The intensity of white opaque lesion
in the phantom was measured as an indication of the hyperthermal effect (B). *P,0.05 (n=5), Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 significantly
increased the hyperthermal effect of HIFU compared to HIFU alone (no PLN).
doi:10.1371/journal.pone.0034333.g002
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HIFU in a concentration-dependent manner (Fig. 3B).
Circulation time and body distribution of Gd-C5F12-PLN
in mice
From the circulation times of Gd-C5F12-PLN-30, Gd-C5F12-
PLN-50, and Gd-C5F12-PLN-100 measured by ICP-AES analysis
of Gd, the plasma half-life of Gd-C5F12-PLN-30 (Fig. 4A), Gd-
C5F12-PLN-50 (Fig. 4B), and Gd-C5F12-PLN-100 (Fig. 4C) was
2.4960.27 hr, 1.5460.29 hr, 1.5860.17 hr, respectively.
The distribution of Gd-C5F12-PLN throughout the body was
also examined to determine the pharmacokinetics and long-term
clearance pathway (Fig. 4D). All Gd-C5F12-PLNs mainly accu-
mulated in the liver and spleen 24 hrs after injection. These results
imply its removal through the reticuloendothelial system (RES) in
the liver and the spleen, resulting in slow secretion of Gd-C5F12-
PLNs through the hepatobiliary pathway.
Accumulation of Gd-C5F12-PLNs in tumor tissues
After intravenous injection of Gd-C5F12-PLN-50 (Fig. 5A) or
Gd-C5F12-PLN-100 (Fig. 5B), the time-dependent accumulations
of both Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 in the tumor
tissue monitored with T1-weighted MR imaging were observed
and plotted, as shown in Figure 5C.
Enhancement of HIFU ablation by Gd-C5F12-PLN in
tumor-bearing mice
To examine the effect of Gd-C5F12-PLN on hyperthermal
tumor cell ablation of HIFU, HIFU was applied to a subcutaneous
tumor model in mice injected with Gd-C5F12-PLN-100 or vehicle
(Fig. 6). The ablated region in T1WI and H&E staining
corresponded with the dead cell area denoted by NADH staining.
The tumor tissues after sonication was also examined in a paraffin-
imbedded specimen to cytologically confirm that the ablated area
contained few abnormal cells (Fig. 7). HIFU treatment with Gd-
Figure 3. Concentration-dependent effect of Gd-C5F12-PLN on the hyperthermal property of HIFU in the tissue-mimicking gel
phantom. The effect of Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 at different concentrations on the hyperthermal property of HIFU was examined in
the phantom (A); the effect was quantified by the intensity of the opaque lesion (B). The Gd-C5F12-PLN concentration was determined by the
phospholipid concentration, which is the main component of Gd-C5F12-PLN.
doi:10.1371/journal.pone.0034333.g003
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or HIFU alone (p=,0.025, n=6) (Fig. 7, lower panel).
Discussion
Although microbubble contrast agents are known to enhance
the therapeutic effect of HIFU ablation [15,16], no contrast agents
are being used clinically because of its short plasma half-life. We
thus designed and prepared gas-filled nanobubbles (W=30–
100 nm) that are smaller than microbubble contrast agents
(W=1–5 mm) to increase their stability (Fig. 1A). Even though
the stability of nanobubbles is still controversial because of its very
high Laplace pressure resulting in quick dissolution and rapid
disappearance [17,18], it has been reported that nanobubbles can
form freely and remain stable for long periods of time due to a
lower interfacial curvature with a high contact angle resulting in
stability of nanobubble by reduction of the Laplace pressure [19–
21]. Our in vitro stability data showed that IC50 of Gd-C5F12-
PLN-50 and 100 was three times longer than that of SonoVue
(Fig. 1E).Our nanobubbles mainly composed of biocompatible
phospholipids were infused with decafluoropentane gas, resulting
that Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 enhanced the
hyperthermal property of HIFU in both a size- and concentration-
dependent manner (Fig. 2 and 3). This enhancement of the
hyperthermal effect could reduce the HIFU energy required to
ablate a tumor, thus reducing the procedure time and the side
effects of HIFU, such as skin burns.
Gd-C5F12-PLN seems cleared through biliary excretion through
RES of liver and the spleen (Fig. 4D). The biliary clearance
pathway of the Gd-C5F12-PLN suggests that the Gd-conjugated
nanobubbles might not cause nephrogenic system fibrosis (NSF), a
common complication of small molecular weight Gd chelates [22].
A Gd-conjugated lipid nanoparticle similar to our Gd-C5F12-PLN
had little effect on nephrogenic system fibrosis [23]. In addition to
the clearance pathway bypassing NSF, we only used 40% of the
recommended clinical dose of Gd (0.1 mmoles/kg), suggesting that
the Gd-C5F12-PLN might increase the margin of safety in treating
patients.
As intended, the nano-sized Gd-C5F12-PLN remained in
circulation long enough to be used in HIFU, comparable to
microbubble contrast agents (Fig. 4). The plasma half-lives of Gd-
C5F12-PLN-50 and Gd-C5F12-PLN-100 in mice were
Figure 4. Circulation and distribution of Gd-C5F12-PLNs in mice. ICP-AES analysis of Gd in the blood after tail vein injection of the Gd-C5F12-
PLNs showed that plasma half-life of Gd-C5F12-PLN-30 was 2.4961.27 (A), Gd-C5F12-PLN-50 was 1.5460.29 (B), and Gd-C5F12-PLN-100 was 1.5860.17
(C). The body distribution of Gd-C5F12-PLNs was determined by [Gd] quantified by ICP-AES 24 hours after administering Gd-C5F12-PLNs in mice (D).
doi:10.1371/journal.pone.0034333.g004
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longer than 5 hrs in humans based on the allometric scale between
mice and humans [24]. Because Gd-C5F12-PLNs had a long
circulation time, HIFU agents will maintain their therapeutic
effects during treatment, which can take several hours to effectively
ablate a large tumor. In addition, the long circulation time also
provides a window for the agent to accumulate in tumor tissues
that have highly permeable, angiogenic microvessels (i.e., EPR).
Gd-C5F12-PLN-50 and Gd-C5F12-PLN-100 monitored by T1WI
continuously increased in the tumor tissues until at least 4 hrs after
injection (Fig. 5). The tumor accumulation allows various
treatment options in HIFU therapy. HIFU treatment can used
after a bolus injection of the HIFU agent, or after it accumulates in
tumor tissues by EPR. The effects of HIFU treatments with Gd-
C5F12-PLNs should to be examined in detail for various stages and
types of tumors to help design therapeutic plans for HIFU
ablation. The accumulation of the Gd-C5F12-PLN-50 in tumor
tissues is much higher than Gd-C5F12-PLN-100, probably due to
their relative stabilities in vivo (Fig. 5C). Thus Gd-C5F12-PLN-50
may be useful for the delayed HIFU ablation after it accumulates
in tumor tissues, although Gd-C5F12-PLN-100 has a greater
hyperthermal effect (Fig. 2). Gd-C5F12-PLN-50 may also have
potential advantages to design its tumor-specific delivery using a
molecular targeting technique, which also requires a long
circulation time.
Our gas-filled nanobubbles were conjugated with Gd-DTPA to
be detectable by MRI. Gd-C5F12-PLN had paramagnetic
properties by SQUID (Fig. 1B) and T1 enhancement in mice
(Fig. 5). Ten percent of the phospholipids in Gd-C5F12-PLNs were
conjugated with Gd through chelation with DMPE-DTPA
(Table 1). MR imaging with the Gd-C5F12-PLN may provide
various advantages, such as visualizing the HIFU agent in the
tumor tissue to be ablated, diagnosing of hyper-vascular tumor
tissues as a blood pool agent, and determining the HIFU treatment
time by monitoring accumulation of the HIFU agent in the tumor.
Despite the many advantages of Gd-C5F12-PLNs in enhancing
HIFU ablation, there are still issues to address before using Gd-
C5F12-PLN clinically. First, inertial cavitation from combining
HIFU and gas-filled Gd-C5F12-PLNs is unpredictable and cause
complications. This risk has been a barrier to using microbubble
agents clinically, as well. Because Gd-C5F12-PLN is much smaller
than microbubbles, the potential complications of acoustic
Figure 5. Accumulation of Gd-C5F12-PLNs in tumor tissues in mice. The tumor tissues were monitored with T1-weighted imaging for 8 hours
after injection of Gd-C5F12-PLN-50 (A) and the Gd-C5F12-PLNs-100 (B). The changes of T1 intensity were plotted in C.
doi:10.1371/journal.pone.0034333.g005
Figure 6. The effect of the Gd-C5F12-PLN-100 on HIFU tumor ablation in the subcutaneous tumor model. The tumor ablation by HIFU
was monitored by gadolinium -enhanced T1-weighted imaging before and after HIFU treatment. The contrast-enhanced images were subtracted
from the image before enhancement. The arrow indicates the HIFU orientation (upper panel). The HIFU ablation was also examined by H&E and
NADH staining of frozen specimens to confirm the ablated area (lower panel).
doi:10.1371/journal.pone.0034333.g006
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were removed by RES and excreted via the hepatobiliary
pathway, thus the risk of nephrogenic systemic fibrosis is likely
lower than Gd-based MR contrast agents. However, the effect of
HIFU-induced hyperthermia on Gd chelation of the nanobubble-
shas not been well studied, therefore HIFU might release free
gadolinium, although it might be minimal. Once these issues are
solved, Gd-C5F12-PLN has a great deal of potential in clinical
HIFU therapy.
Taken together, in vitro and in vivo data demonstrated that Gd-
C5F12-PLN, which is stable and detectable by MR imaging, is a
potential theragnostics for the MR-guided HIFU ablation. Even
though we only assessed the role of Gd-C5F12-PLN in enhancing
the hyperthermal effect of HIFU therapy, we are convinced it has
many other applications for focused ultrasound, such as ultra-
sound-assisted drug/gene delivery or blood-brain barrier opening,
which should be characterized in future studies.
Supporting Information
Video S1 Hyperthermal effect of HIFU on a acrylamide
gel phantom in the absence of Gd-C5F12-PLN. The real-
time video recording was taken during the whole HIFU exposure
time.
(WMV)
Video S2 Hyperthermal effect of HIFU on a acrylamide
gel phantom containing Gd-C5F12-PLN-30. The real-time
video recording was taken during the whole HIFU exposure time.
(WMV)
Video S3 Hyperthermal effect of HIFU on a acrylamide
gel phantom containing Gd-C5F12-PLN-50. The real-time
video recording was taken during the whole HIFU exposure time.
(WMV)
Video S4 Hyperthermal effect of HIFU on a acrylamide
gel phantom containing Gd-C5F12-PLN-100. The real-time
video recording was taken during the whole HIFU exposure time.
(WMV)
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